News und Analysen

The biotech industry features many prominent companies that command plenty of attention on the market. And since the year started, few biotechs have made more noise than Viking Therapeutics (NASDAQ:

Healthcare giants sometimes pay decent dividend distributions, and UnitedHealth Group (NYSE: UNH) certainly falls into that category. In the wake of difficult circumstances, however, investors might

Healthcare giants sometimes pay decent dividend distributions, and UnitedHealth Group (NYSE: UNH) certainly falls into that category. In the wake of difficult circumstances, however, investors might

Cathie Wood is known for two things: picking out innovators that will go on to score a win over the long run, and getting in on these stocks at a great price. The founder and chief executive officer

Generating dividend income can be an excellent way to put your cash to work. It can provide you with an extra stream of cash flow to diversify your income and help you pay bills, or perhaps fund a

Generating dividend income can be an excellent way to put your cash to work. It can provide you with an extra stream of cash flow to diversify your income and help you pay bills, or perhaps fund a

On June 2, Intellia Therapeutics' (NASDAQ: NTLA) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words

Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper.

Three Motley Fool

Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper.

Three Motley Fool

Shares of Geron (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades.

On June 6, the U.S. Food

On April 19, U.S. Rep. Thomas Kean Jr., R-N.J., bought shares of Illumina (NASDAQ: ILMN) and sold shares of Nike (NYSE: NKE), according to a May 31 filing. Although it's unclear exactly how many

On April 19, U.S. Rep. Thomas Kean Jr., R-N.J., bought shares of Illumina (NASDAQ: ILMN) and sold shares of Nike (NYSE: NKE), according to a May 31 filing. Although it's unclear exactly how many

On April 19, U.S. Rep. Thomas Kean Jr., R-N.J., bought shares of Illumina (NASDAQ: ILMN) and sold shares of Nike (NYSE: NKE), according to a May 31 filing. Although it's unclear exactly how many

Many billionaires are active on Wall Street and largely built their wealth that way. So, paying attention to their moves and the stocks they invest in can teach us a lot. Of course, blindly

Many billionaires are active on Wall Street and largely built their wealth that way. So, paying attention to their moves and the stocks they invest in can teach us a lot. Of course, blindly

Cathie Wood doesn't take any trading days off. The co-founder and CEO of Ark Invest publishes her transactions for the family of exchange-traded funds she manages. She didn't make a lot of moves on

Dividend growth stocks can make for excellent long-term investments. Their ongoing rate increases allow investors to generate more in dividend income than if they were to just invest in a stale

Viking Therapeutics (NASDAQ: VKTX) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the metabolic disease specialist has, so far, delivered a staggering 208% return on

A few years ago, in the race to launch a COVID-19 vaccine, Pfizer (NYSE: PFE) stock was a hot buy after the company ended up with a highly successful product in Comirnaty. The uncertainty

A few years ago, in the race to launch a COVID-19 vaccine, Pfizer (NYSE: PFE) stock was a hot buy after the company ended up with a highly successful product in Comirnaty. The uncertainty

When you look at the stock market, valuations can seem stretched for a lot of the megacap names -- not all -- but there are still plenty of deals to be had. In today's video, I will look into a few